NCT00179608View on ClinicalTrials.gov

Study of the Combination of Lenalidomide and DTIC (Dacarbazine) in Patients With Metastatic Malignant Melanoma Previously Untreated With Systemic Chemotherapy

PHASE1CompletedINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

September 1, 2005

Primary Completion Date

June 1, 2007

Study Completion Date

June 1, 2007

Conditions
Malignant Melanoma
Interventions
DRUG

CC-5013

Trial Locations (1)

77030-4009

MD Anderson Cancer Center, Houston

Sponsors

Lead Sponsor

Celgene
All Listed Sponsors
collaborator

Prologue Research International

INDUSTRY

lead

Celgene

INDUSTRY

NCT00179608 - Study of the Combination of Lenalidomide and DTIC (Dacarbazine) in Patients With Metastatic Malignant Melanoma Previously Untreated With Systemic Chemotherapy | Biotech Hunter | Biotech Hunter